Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking their seventh partnership and enhancing their long-term relationship [1][2]. Group 1: Strategic Collaboration - Innovent Biologics, along with its subsidiaries, has entered into a strategic collaboration with Eli Lilly to promote global R&D of innovative drugs in oncology and immunology [1]. - The agreement allows Innovent to leverage its mature antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept validation in China [1][2]. - Eli Lilly will obtain exclusive global development and commercialization rights for the projects outside Greater China, while Innovent retains all rights within Greater China [1]. Group 2: Financial Terms - Innovent will receive an upfront payment of $350 million, with the potential to earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [2]. - The company will also be entitled to a tiered sales share based on net sales of each product outside Greater China [2]. Group 3: Innovation Ecosystem - This collaboration breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates Innovent's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2]. - The partnership underscores Innovent's core R&D strength and aims to accelerate the translation of scientific discoveries into impactful medical solutions for global patients [2].

Group 1 - The core viewpoint of the article is that the strategic partnership between Borui Pharmaceutical and China Resources Sanjiu is expected to enhance sales capabilities and support R&D efforts for the BGM0504 injection product, leading to a "buy" rating for Borui Pharmaceutical [1][2][3]. Group 2 - On August 1, 2025, Borui Pharmaceutical signed a cooperation and R&D agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 in mainland China, granting exclusive development and commercialization rights while retaining ownership of the product [2]. - China Resources Sanjiu will pay up to 282 million yuan in milestone payments for R&D and additional sales milestone payments, which will be the lower of 50% of the clinical R&D costs for new indications or 28.5 million yuan [2]. - The collaboration allows Borui to leverage China Resources Sanjiu's leading OTC channel capabilities to enhance sales, while China Resources Sanjiu benefits from an expanded product line and a share of sales service fees [3]. Group 3 - Borui Pharmaceutical has a rich pipeline in innovative drugs and complex generics, with BGM1812 in preclinical stages and BGM0504 tablets having received IND application acceptance, expected to enter clinical phase 1 within the year [4]. - The company anticipates deepening cooperation with China Resources Sanjiu as more products are launched, particularly the oral BGM0504 tablets, which could significantly increase domestic sales [4]. - Profit forecasts for Borui Pharmaceutical estimate net profits of 260 million yuan, 300 million yuan, and 430 million yuan for 2025, 2026, and 2027 respectively, with a current market P/E valuation of 160, 139, and 97 times [4].